Abstract:PD-(L)1 inhibitors have provided new treatment approaches for patients with NSCLC; however, resistance to PD-(L)1 inhibitors or low PD-L1 expression may limit clinical benefit. Tislelizumab, a monoclonal antibody with high affinity and specificity for PD-1, was recently approved in China for the treatment of previously treated classical Hodgkin lymphoma. Tislelizumab was engineered to minimize binding to FcɣR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti- PD-1 therapy. Preliminary reports from this study (NCT04068519) showed that tislelizumab monotherapy was generally well tolerated and demonstrated antitumor activity in Chinese patients with advanced solid tumors. We now present data from patients with NSCLC. This multi-arm, open-label, nonrandomized phase 1/2 study evaluated safety/tolerability, antitumor activity, and survival in patients with histologically/cytologically confirmed advanced solid tumors treated with tislelizumab. Eligible patients progressed on, or were intolerant to, their last standard antitumor treatment and were anti-PD-(L)1 therapy treatment-naïve. Patients received intravenous tislelizumab 200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity. Patients were considered PD-L1-positive if ≥10% of their tumor cells had PD-L1 membrane staining at any intensity using the VENTANA PD-L1 (SP263) assay. Antitumor response was assessed by RECIST v1.1, overall survival (OS) was estimated by Kaplan-Meier analysis, and safety/tolerability was examined by monitoring adverse events (AEs). As of 01 December 2018, 56 patients with NSCLC (nonsquamous, n=31 [55%]; squamous, n=25 [45%]) were enrolled. Forty patients (71%) were male, 53 (95%) had metastatic disease, and 23 (41%) had never smoked; one patient each had an EGFR mutation or ALK rearrangement. Patients were heavily pretreated, with 16 patients (29%) receiving ≥3 lines of prior systemic therapy. The most common treatment-related AEs (TRAEs) were increased AST (n=14; 25%), increased ALT (n=13; 23%), and rash (n=8; 14%). Increased AST (n=3; 5%) and increased ALT (n=2; 4%) were the only grade ≥3 TRAEs occurring in ≥2 patients. Immune-related AEs (irAE) were reported in 12 patients (21%) and were generally of low severity, including 1 patient with grade 2 pneumonitis; 4 patients (7%) experienced a grade ≥3 irAE. The objective response rate (ORR) was 18% (95% CI: 8.9, 30.4), with an ORR of 17% (95% CI: 4.7, 37.4) and 19% (95% CI: 7.5, 37.5) in patients who were PD-L1-positive (n=24) and PD-L1-negative (n=31), respectively. With a median follow-up of 14.6 months (95% CI: 12.0, 15.6), median OS was not reached in patients with NSCLC. Updated data with a follow-up of ≥2 years will be presented, including OS. Tislelizumab was generally well tolerated and demonstrated antitumor activity in NSCLC patients regardless of PD-L1 expression status. Tislelizumab is being evaluated as a single agent or with chemotherapy in phase 3 studies in NSCLC patients (NCT03358875, NCT03594747, and NCT03663205).

Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study.

Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) As Salvage Treatment for Advanced Gastric Adenocarcinoma: Preliminary Results of an Open-Label, Multi-Cohort, Phase Ib/II Clinical Study.

Recombinant Humanised Anti-Pd-1 Monoclonal Antibody (js001) Treatment for Patients with Refractory or Metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label, Phase 1b/2, Clinical Study

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study

Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.

Phase 1/2 Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Advanced Solid Tumors: Interim Results from Dose-Escalation.

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

Enlonstobart: First Approval

357 GLS-010 (zimberelimab), a Novel Fully Human Anti-Pd-1 Mab in Chinese Patients with Recurrent/metastatic Cervical Cancer: Results from a Multicenter, Open-Label, Single-Arm Phase II Trial

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

Penpulimab Plus Platinum-Based Chemotherapy Combined with Anlotinib in First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer: A Single-Arm, Open-Label Phase Ⅱ Study (ALTN-AK105-II-06).

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study

Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts.

Efficacy and Safety of the Anti-PD-L1 Monoclonal Antibody Socazolimab for Recurrent or Metastatic Cervical Cancer: A Phase I Dose-Escalation and Expansion Study